3-(8-(2,4-difluorophenyl)-1-methyl-2-oxo-1,2-dihydropyrido[2,3-d]pyridazin-3-yl)-4-methyl-N-(1-methyl-1H-pyrazol-5-yl)benzamide | 1214882-26-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 3-(8-(2,4-difluorophenyl)-1-methyl-2-oxo-1,2-dihydropyrido[2,3-d]pyridazin-3-yl)-4-methyl-N-(1-methyl-1H-pyrazol-5-yl)benzamide
• 英文别名: 3-[8-(2,4-difluorophenyl)-1-methyl-2-oxopyrido[2,3-d]pyridazin-3-yl]-4-methyl-N-(2-methylpyrazol-3-yl)benzamide
• CAS: 1214882-26-4
• 化学式: C₂₆H₂₀F₂N₆O₂
• 分子量: 486.481
• InChiKey: LGZUPPLJIFGTHZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  36
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  93
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• [EN] PYRIDAZINO- PYRIDINONE COMPOUNDS FOR THE TREATMENT OF PROTEIN KINASE MEDIATED DISEASES.<br/>[FR] COMPOSÉS PYRIDAZINO-PYRIDINONE UTILISÉS POUR LE TRAITEMENT DE MALADIES MÉDIÉES PAR UNE PROTÉINE KINASE
  申请人：AMGEN INC

  公开号：WO2010025201A1

  公开（公告）日：2010-03-04

  The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A, R1, R2, R3, R4, R5, R6, X and n are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of p38 map kinase mediated diseases including rheumatoid arthritis, psoriasis, chronic obstructive pulmonary disease, pain and other inflammatory disorders, as well as intermediates and processes useful for the preparation of compounds of Formula (I).

  本发明涵盖了一类新化合物，用于预防和治疗蛋白激酶介导的疾病，包括炎症和相关疾病。这些化合物具有一般的化学式I，其中A、R1、R2、R3、R4、R5、R6、X和n在此定义。该发明还包括包括化学式I中一种或多种化合物的药物组合物，用于治疗p38 MAP激酶介导的疾病，包括类风湿性关节炎、牛皮癣、慢性阻塞性肺病、疼痛和其他炎症性疾病，以及用于制备化学式I化合物的中间体和工艺。
• Pyridazino-pyridinone Compounds and Methods of Use
  申请人：Pettus Liping H.

  公开号：US20110275629A1

  公开（公告）日：2011-11-10

  The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , X and n are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of p38 map kinase mediated diseases including rheumatoid arthritis, psoriasis, chronic obstructive pulmonary disease, pain and other inflammatory disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.

  本发明涉及一类新型化合物，用于预防和治疗蛋白激酶介导的疾病，包括炎症和相关疾病。该化合物具有一般式I，其中A、R1、R2、R3、R4、R5、R6、X和n在此定义。本发明还包括含有一种或多种I式化合物的药物组合物，以及用于治疗p38 MAP激酶介导的疾病，包括类风湿性关节炎、牛皮癣、慢性阻塞性肺疾病、疼痛和其他炎症性疾病的化合物和组合物的用途，以及制备I式化合物的中间体和过程。
• Pyridazino- pyridinone compounds for the treatment of protein kinase mediated diseases.
  申请人：Amgen, Inc

  公开号：EP2334674B1

  公开（公告）日：2012-06-06
• PYRIDAZINO- PYRIDINONE COMPOUNDS FOR THE TREATMENT OF PROTEIN KINASE MEDIATED DISEASES.
  申请人：Amgen, Inc

  公开号：EP2334674A1

  公开（公告）日：2011-06-22
• US8455495B2
  申请人：——

  公开号：US8455495B2

  公开（公告）日：2013-06-04